Pirbuterol in the treatment of bronchial asthma.

Pirbuterol, a new anti-asthmatic compound, was tested in 21 male outpatients with reversible bronchospastic disease during 12 months in different dosis regimens in order to determine the extent and duration of bronchodilator activity, the optimum multiple dose-schedule, the incidence, type and degree of side effects, and the cardiovascular as well as hematologic, renal and hepatic function after oral administration. All patients were checked by monthly pulmonary function studies, E.C.G. and extensive laboratory tests. Aso slit lamp examinations were performed. Pirbuterol is a well-tolerated bronchodilator which appears to be of clinical importance in the long-term treatment of bronchospastic disease.